Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artemisia dracunculus pollen, commonly known as tarragon pollen, is a biological substance used in the field of allergology as an allergen extract. It is primarily indicated for the diagnosis of tarragon-induced allergic sensitization via skin prick testing and for the treatment of allergic rhinitis and conjunctivitis through allergen immunotherapy (AIT). The extract contains various proteins that act as allergens; when introduced to a sensitized individual, these proteins cross-link specific IgE antibodies bound to high-affinity receptors (FcεRI) on the surface of mast cells and basophils, triggering the release of inflammatory mediators. In a therapeutic context, repeated administration of the extract in increasing doses induces immunological tolerance by promoting the expansion of regulatory T cells (Tregs), increasing the production of IL-10, and stimulating the synthesis of allergen-specific IgG4 antibodies which act as blocking antibodies to prevent IgE-mediated responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artemisia dracunculus pollen.